Protocol Ledger

NCT07700667 · Phase II · RECRUITING

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Interventional Phase II clinical trial protocol NCT07700667 sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-13 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07700667
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07700667
Protocol FieldVerified Registry Value
NCT IdentifierNCT07700667
Consolidated Lead SponsorSichuan Kelun-Biotech Biopharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2026-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07700667
Hospital Research SiteLocationSite Profile
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI